You're assuming that:
* the licencee would have prioritised fast clinical trials
* the licencee could and would have recruited central line patients faster than RAC has.
Amyway, I don't think that it's accurate to say that AML EMD is regarded by RAC as a "fall back". It was and still is regarded as the fastest way to approval. It's "fall back" only in the sense that as at today FTO and cardioprotection are both higher risk and they might both flop, so AML EMD sets a floor value.
Ann: Quarterly Activity Report & Appendix 4C, page-47
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.010(0.55%) |
Mkt cap ! $307.3M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.84 | $1.78 | $271.2K | 150.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 349 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |